Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase

J. M. Goldman, R. Szydlo, M. M. Horowitz, R. P. Gale, R. C. Ash, K. Atkinson, K. A. Dicke, E. Gluckman, R. H. Herzig, A. Marmont, T. Masaoka, P. B. McGlave, H. Messner, R. J. O'Reilly, J. Reiffers, A. A. Rimm, B. Speck, J. A. Veum-Stone, J. R. Wingard

Research output: Contribution to journalArticlepeer-review

184 Scopus citations

Abstract

We analyzed the outcome of 450 HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in chronic phase performed between 1985 and 1990 and reported to the International Bone Marrow Transplant Registry (IBMTR). All patients received either hydroxyurea (n = 292) or busulfan (n = 158) to treat their CML before transplant. The median interval between diagnosis and transplant was 10 months (range, 1 to 191). Patients treated with hydroxyurea had a higher probability (95% confidence interval) of leukemia-free survival (LFS) at 3 years than those treated with busulfan (61% [51% to 70%] v 45% [36% to 55%], P < .0003). Probability of LFS was also higher in patients transplanted within 1 year of diagnosis (61% [53 to 68%] v 47% [38% to 57%], P < .0001). After adjustment for patient and transplant covariables in a multivariate analysis, prior chemotherapy and duration of disease pretransplant were independently associated with LFS. These data support the use of hydroxyurea rather than busulfan and transplant within 1 year of diagnosis for patients with CML and an HLA-identical sibling.

Original languageEnglish (US)
Pages (from-to)2235-2238
Number of pages4
JournalBlood
Volume82
Issue number7
DOIs
StatePublished - 1993

Fingerprint Dive into the research topics of 'Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase'. Together they form a unique fingerprint.

Cite this